Inspire Investing LLC Acquires New Position in Medpace Holdings, Inc. $MEDP

Inspire Investing LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,647 shares of the company’s stock, valued at approximately $2,610,000.

Several other large investors have also bought and sold shares of the business. Dorsey Wright & Associates acquired a new stake in Medpace during the 3rd quarter worth $5,082,000. Capital Fund Management S.A. raised its stake in Medpace by 129.5% during the 3rd quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock worth $16,665,000 after buying an additional 18,287 shares during the period. Victory Capital Management Inc. raised its stake in Medpace by 32.9% during the 3rd quarter. Victory Capital Management Inc. now owns 30,539 shares of the company’s stock worth $15,702,000 after buying an additional 7,565 shares during the period. Fisher Asset Management LLC raised its stake in Medpace by 9.9% during the 3rd quarter. Fisher Asset Management LLC now owns 137,746 shares of the company’s stock worth $70,824,000 after buying an additional 12,399 shares during the period. Finally, Intech Investment Management LLC raised its stake in Medpace by 31.9% during the 3rd quarter. Intech Investment Management LLC now owns 18,395 shares of the company’s stock worth $9,458,000 after buying an additional 4,448 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Price Performance

MEDP opened at $457.09 on Thursday. The company has a market capitalization of $13.05 billion, a price-to-earnings ratio of 28.73, a P/E/G ratio of 2.34 and a beta of 1.18. The business’s 50-day moving average price is $454.30 and its two-hundred day moving average price is $500.75. Medpace Holdings, Inc. has a 1 year low of $294.07 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the prior year, the firm earned $3.67 earnings per share. Medpace’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and lowered their target price for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. BMO Capital Markets dropped their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Robert W. Baird cut their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Royal Bank Of Canada reduced their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Medpace has a consensus rating of “Hold” and an average price target of $467.08.

Insiders Place Their Bets

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 20.50% of the stock is currently owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.